Amgen Inc.
Thesis
Amgen's heavy R&D spending is currently depressing its earnings, making it appear expensive relative to the pharmaceutical industry. However, when considering enterprise value to EBITDA plus R&D, Amgen looks much cheaper and has better growth prospects due to longer patent protection.
Did it work?
inconclusive
confidence: low
The thesis is a valuation argument — that Amgen is cheaper than it appears when R&D is added back to EBITDA and that its longer patent protection supports better growth — but no price performance is available and no time horizon is stated. There are no specific thesis events (e.g., a catalyst or milestone) that can be verified as having occurred or failed. Without either a return figure or confirmable thesis dynamics, the outcome cannot be judged.